Company intelligence / Profile preview
Waypoint Bio
New York City / Manhattan / HQ at "180 Varick Street 6th Floor", New York, United Stateswaypointbio.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Preclinical
01
Overview
Waypoint Bio is developing a platform to rapidly discover and optimize novel cell therapies for solid tumors using in vivo spatial pooled screening. The company has not yet reported clinical results but aims to identify candidates with improved efficacy by directly testing them in mouse models and analyzing hundreds of phenotypes at the single-cell level.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Engineered cell therapies (including CAR T-cells)Engineered exosomes loaded with therapeutic payloads such as siRNAs or mRNAs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Waypoint Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Waypoint Bio.